News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
407,513 Results
Type
Article (32749)
Company Profile (134)
Press Release (374629)
Multimedia
Podcasts (55)
Webinars (9)
Section
Business (103739)
Career Advice (588)
Deals (15040)
Drug Delivery (60)
Drug Development (63601)
Employer Resources (55)
FDA (10885)
Job Trends (8868)
News (192914)
Policy (16883)
Tag
Academia (2116)
Academic (1)
Accelerated approval (12)
Adcomms (22)
Allergies (57)
Alliances (28919)
ALS (79)
Alzheimer's disease (1023)
Antibody-drug conjugate (ADC) (184)
Approvals (10925)
Artificial intelligence (237)
Autoimmune disease (23)
Automation (8)
Bankruptcy (127)
Best Places to Work (7583)
BIOSECURE Act (5)
Biosimilars (79)
Biotechnology (105)
Bladder cancer (118)
Brain cancer (43)
Breast cancer (435)
Cancer (3457)
Cardiovascular disease (183)
Career advice (482)
Career pathing (9)
CAR-T (195)
CDC (33)
Cell therapy (460)
Cervical cancer (29)
Clinical research (53461)
Collaboration (789)
Company closure (4)
Compensation (308)
Complete response letters (25)
COVID-19 (1632)
CRISPR (43)
C-suite (264)
Cystic fibrosis (78)
Data (2982)
Decentralized trials (1)
Denatured (10)
Depression (72)
Diabetes (215)
Diagnostics (4540)
Digital health (17)
Diversity (7)
Diversity, equity & inclusion (18)
Drug discovery (104)
Drug pricing (89)
Drug shortages (8)
Duchenne muscular dystrophy (86)
Earnings (35801)
Editorial (27)
Employer branding (7)
Employer resources (50)
Events (66479)
Executive appointments (540)
FDA (12374)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (7)
Funding (656)
Gene editing (75)
Generative AI (13)
Gene therapy (241)
GLP-1 (386)
Government (2869)
Grass and pollen (3)
Guidances (183)
Healthcare (13340)
HIV (25)
Huntington's disease (15)
IgA nephropathy (29)
Immunology and inflammation (102)
Immuno-oncology (13)
Indications (34)
Infectious disease (1753)
Inflammatory bowel disease (97)
Inflation Reduction Act (9)
Influenza (46)
Intellectual property (71)
Interviews (78)
IPO (7321)
IRA (38)
Job creations (1621)
Job search strategy (449)
Kidney cancer (14)
Labor market (15)
Layoffs (274)
Leadership (4)
Legal (2676)
Liver cancer (89)
Longevity (8)
Lung cancer (509)
Lymphoma (240)
Machine learning (13)
Management (17)
Manufacturing (233)
MASH (67)
Medical device (7145)
Medtech (7154)
Mergers & acquisitions (8104)
Metabolic disorders (502)
Multiple sclerosis (68)
NASH (7)
Neurodegenerative disease (73)
Neuropsychiatric disorders (28)
Neuroscience (1526)
NextGen: Class of 2025 (4175)
Non-profit (3550)
Now hiring (9)
Obesity (215)
Opinion (112)
Ovarian cancer (113)
Pain (81)
Pancreatic cancer (144)
Parkinson's disease (130)
Partnered (13)
Patents (181)
Patient recruitment (214)
Peanut (28)
People (33767)
Pharmaceutical (29)
Pharmacy benefit managers (8)
Phase I (17162)
Phase II (23579)
Phase III (17277)
Pipeline (1597)
Policy (150)
Postmarket research (1960)
Preclinical (6851)
Press Release (35)
Prostate cancer (171)
Psychedelics (39)
Radiopharmaceuticals (250)
Rare diseases (323)
Real estate (3543)
Recruiting (18)
Regulatory (13439)
Reports (19)
Research institute (1988)
Resumes & cover letters (84)
Rett syndrome (6)
RNA editing (5)
RSV (40)
Schizophrenia (65)
Series A (106)
Series B (81)
Service/supplier (2)
Sickle cell disease (51)
Special edition (9)
Spinal muscular atrophy (90)
Sponsored (17)
Startups (2056)
State (1)
Stomach cancer (17)
Supply chain (35)
Tariffs (31)
The Weekly (44)
Vaccines (619)
Venture capital (22)
Weight loss (105)
Women's health (33)
Worklife (4)
Date
Last 7 days (300)
Last 30 days (1254)
Last 365 days (19900)
2025 (13584)
2024 (22780)
2023 (25752)
2022 (33483)
2021 (35402)
2020 (32886)
2019 (28475)
2018 (21413)
2017 (19610)
2016 (18774)
2015 (21750)
2014 (16432)
2013 (13154)
2012 (13966)
2011 (14531)
2010 (13233)
Location
Africa (333)
Alabama (35)
Alaska (5)
Arizona (116)
Arkansas (9)
Asia (24357)
Australia (3945)
California (5353)
Canada (1499)
China (601)
Colorado (239)
Connecticut (238)
Delaware (180)
Europe (50079)
Florida (754)
Georgia (214)
Idaho (31)
Illinois (452)
India (21)
Indiana (231)
Iowa (10)
Japan (162)
Kansas (57)
Kentucky (25)
Louisiana (12)
Maine (9)
Maryland (1157)
Massachusetts (3963)
Michigan (117)
Minnesota (288)
Mississippi (3)
Missouri (57)
Montana (14)
Nebraska (13)
Nevada (45)
New Hampshire (50)
New Jersey (1579)
New Mexico (14)
New York (1591)
North Carolina (652)
North Dakota (5)
Northern California (2543)
Ohio (139)
Oklahoma (10)
Oregon (23)
Pennsylvania (1141)
Puerto Rico (10)
Rhode Island (25)
South America (447)
South Carolina (20)
Southern California (1998)
Tennessee (108)
Texas (953)
United States (20053)
Utah (143)
Virginia (104)
Washington D.C. (44)
Washington State (491)
West Virginia (3)
Wisconsin (53)
407,513 Results for "md anderson cancer center".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
June 25, 2025
·
7 min read
Press Releases
Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology
June 10, 2025
·
3 min read
Press Releases
Bantam Pharmaceutical Announces Activation of First Phase 1 Clinical Trial Site at MD Anderson Cancer Center
February 20, 2025
·
3 min read
Business
OneOncology Partners with Anderson Area Cancer Center
Anderson Area Cancer Center and OneOncology announced a finalized partnership to enhance the delivery of cancer services in and around Anderson, South Carolina.
June 24, 2024
·
2 min read
Press Releases
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
March 11, 2025
·
6 min read
Press Releases
NYU Langone Health Brings on Two Acclaimed Cancer Experts to Lead Ambitious New Gastrointestinal Cancer Center
September 8, 2025
·
6 min read
Press Releases
Texas Children’s Hospital and UT MD Anderson Announce Joint Venture to End Childhood Cancer
February 19, 2025
·
4 min read
Business
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
April 16, 2024
·
8 min read
Business
Sibylla Biotech and MD Anderson Announce Strategic Collaboration to Discover and Develop Small-Molecule Protein Degraders
Sibylla Biotech and The University of Texas MD Anderson Cancer Center announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as Folding Interfering Degraders, which disrupt the proper folding of target proteins and lead to their degradation.
June 12, 2024
·
4 min read
Business
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a multi-year strategic development collaboration to expand the evaluation of REZLIDHIA ® (olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers.
December 8, 2023
·
11 min read
1 of 40,752
Next
